Progress in the understanding of the biology and therapy of acute myeloid leukemia (AML)
is occurring rapidly. Since 2017, nine agents have been approved for various indications in …

In 1957, Hillestad et al. defined acute promyelocytic leukemia (APL) for the first time in the
literature as a distinct type of acute myeloid leukemia (AML) with a “rapid downhill course” …

The NCCN Guidelines for Acute Myeloid Leukemia (AML) provide recommendations for the
diagnosis and treatment of adults with AML based on clinical trials that have led to …

Aerobic organisms possess numerous antioxidant enzymatic families, including catalases,
superoxide dismutases (SODs), peroxiredoxins (PRDXs), and glutathione peroxidases …

Background Several important treatment and supportive care strategies have been
implemented over the past 4 decades in the management of acute myeloid leukemia (AML) …

Background All-trans retinoic acid (ATRA) with chemotherapy is the standard of care for
acute promyelocytic leukemia (APL), resulting in cure rates exceeding 80%. Pilot studies of …

Background Acute promyelocytic leukaemia is a chemotherapy-sensitive subgroup of acute
myeloid leukaemia characterised by the presence of the PML–RARA fusion transcript. The …

Purpose The initial results of the APL0406 trial showed that the combination of all-trans-
retinoic acid (ATRA) and arsenic trioxide (ATO) is at least not inferior to standard ATRA and …

The unraveling of the pathophysiology of acute myeloid leukemia (AML) has resulted in
rapid translation of the information into clinical practice. After more than 40 years of slow …

In the past few years research in the underlying pathogenic mechanisms of acute myeloid
leukaemia (AML) has led to remarkable advances in our understanding of the disease …